

Company Overview

Acasti Pharma is a biopharmaceutical innovator that has historically focused on advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. Acasti conducted two Phase 3 clinical trials: the TRILOGY 1, CaPre® achieved a 30.5% reduction in triglyceride levels at 12 weeks and 36.7% reduction in triglyceride levels at 26 weeks, as well as 42.2% reduction in triglyceride levels among patients receiving CaPre while on background statin therapy at 12 weeks. Despite positive results in the CaPre arm, the TRILOGY 1 study did not reach statistical significance. In TRILOGY 2, CaPre achieved 30.4% median reduction in triglycerides at 12 weeks and 38.4% at 26 weeks, but did not achieve statistical significance for the primary endpoint.

Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics

Jul 23 2021, 12:00 AM EDT

Acasti Pharma Provides Fiscal 2021 Year-End Business Update

Jun 22 2021, 12:00 AM EDT

Stock Overview

Symbol ACST
Exchange Nasdaq
Market Cap 46.2m
Last Price \$0.47
52-Week Range \$0.17 - \$1.22

07/23/2021 04:00 PM EDT

Investor Relations

Crescendo Communications, LLC
Chrysler Building
405 Lexington Ave
9th Floor, Suite 9034
New York, NY 10174
T: 212-671-1020
ACST@crescendo-ir.com

Management Team

Jan D'Alvise

President and CEO

Pierre Lemieux, Ph.D.

Chief Operating and Scientific Officer, Co-Founder

Brian D. Ford CPA-CA

Chief Financial Officer

Acasti Pharma Inc.

3009 Boul. de la Concorde E.
Suite 102
Laval, Québec H7E 2B5
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.